Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that compound 3, a tetrahydropyridoindole carboxymethylated at position 5, significantly inhibited sorbitol accumulation in both rat eye lenses and tissues affected by diabetes, indicating its potential as a lead compound for ALR2 inhibition.

GLP-1 receptor agonists may help or harm hair health, needing more research.

This review discusses severe insulin resistance syndromes, highlighting their diagnostic challenges, potential novel therapies like leptin replacement, and suggests metformin and lifestyle changes in its absence; no new clinical results are reported.

This study reports that a novel series of compounds can potently and selectively inhibit glycogen synthase kinase-3, which activates glycogen synthase in insulin receptor-expressing cells and primary rat hepatocytes.

This review discusses indole-based bifunctional aldose reductase inhibitors and antioxidants for diabetic complications and chronic inflammation-related pathologies, but reports no new clinical results.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This review discusses the antidiabetic properties of secondary metabolites found in 112 plants, but reports no new clinical results.

This narrative review explores current evidence on GLP-1 receptor agonists and hair-related conditions, noting reports of both hair regrowth and potential associations with telogen effluvium.

This review suggests weak associations between GLP-1 receptor agonists and increased reports of hair loss, particularly with semaglutide and tirzepatide, while cases of hair regrowth were also occasionally documented.

In this study with diabetic rats, the researchers found that combining Amoxicillin/Clavulanate with metformin may enhance the glucose-lowering effects of metformin, without affecting cholesterol, triglycerides, or certain electrolytes.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

In this case report, researchers documented a rare instance of trans-epidermal elimination of insulin formulation in a 45-year-old woman with diabetes, suggesting that insulin or its excipients may have caused a granulomatous reaction leading to skin lesions at injection sites and impaired diabetes control.

This study found that DPP4 inhibition in mice can enhance hair follicle activation and regeneration, suggesting a potential therapeutic strategy for improving hair growth and wound-induced hair follicle neogenesis.

This article describes how a new blood glucose management service at the NIH Clinical Center improved safety and patient outcomes for hospitalized patients with diabetes.

This study reports that metreleptin treatment in a boy with congenital generalized lipodystrophy significantly improved metabolic complications and overall health outcomes during the first year of therapy.

This study found that Diabetex significantly improved wound healing and reduced fasting blood sugar in diabetic rats, showing potential as a safe and economic treatment strategy for diabetic-resistant wounds.

This study found that autologous nonmyeloablative hematopoietic stem cell transplantation may help some newly-onset type 1 diabetes patients become insulin-free, although gastrointestinal and other mild side effects were observed.

This editorial examines how GLP-1 receptor agonists, providing significant weight loss and cardiovascular benefits, can be integrated into a comprehensive obesity treatment alongside diet and lifestyle changes, but highlights the need for further guidance on their real-world application and multidisciplinary care.

This study found that semaglutide significantly reduced body weight in almost 80% of obese PCOS patients unresponsive to lifestyle changes, often normalizing menstrual cycles with few side effects.

This study found that metformin treatment significantly decreased gremlin levels and improved insulin resistance in patients with polycystic ovary syndrome.

This study observed that among patients starting Semaglutide therapy at 0.25-2mg weekly, approximately 0.80-0.83% reported non-scarring hair loss within six months, suggesting the drug does not significantly increase hair loss risk.

In this randomized trial, metformin and pioglitazone both improved certain clinical and metabolic indices in women with PCOS, with pioglitazone showing potential as an alternate treatment for those intolerant to metformin.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.

This review discusses the pharmacological actions and potential therapeutic benefits of ginsenoside compound K for metabolic disorders, reports no new clinical results, and suggests further research on its bioavailability and toxicity.

In this study, voglibose, commonly used for diabetes management, was found to reduce melanin synthesis and inhibit melanogenic signaling pathways in B16F10 melanoma cells, suggesting it could be repurposed for treating hyperpigmentation disorders with confirmed topical safety in human tests.

HPLC may detect prediabetes and diabetes earlier than Immunoturbidimetry because it shows higher A1c levels.